Digest Network Come funziona
Network
/
Società
Za
Non verificato

Zai Lab Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteScienza

65 comunicati stampa

Guarda tutti i comunicati
22/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
18/04/2026
Eventi
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
17/04/2026
Eventi
Industria
Web e Social Network
Telefonia e Varie
Igiene alimentare
Medicina - Varie
Biotecnologia
Medicina nucleare
Salute
Farmaceutica
Sanità
Oncologia
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
01/04/2026
Mercato del lavoro
Industria
Oncologia
Salute
Medicina - Varie
Medicina nucleare
Farmaceutica
Biotecnologia
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
17/03/2026
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
26/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
10/02/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
13/01/2026
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
06/01/2026
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0
05/01/2026
Eventi
Web e Social Network
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
Fonte
Zai Lab Limited
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0